Disitamab Vedotin Plus Cadonilimab

Phase 2Antibody–drug conjugate

Disitamab Vedotin Plus Cadonilimab is one of 3 small molecule programs targeting Bile Duct Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct AdenocarcinomaActive, not recruiting

Bile Duct AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Bile Duct Adenocarcinoma

#DrugCompanyPhaseTrials

Surufatinib

HHutchison Medipharma Limited

Phase 2

—2

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

—3

Disitamab Vedotin Plus Cadonilimab

ZZhejiang Cancer Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Disitamab Vedotin

NCT06572319

Clinical

Trials by Indication[1]

Disitamab Vedotin1 trial

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Recruiting·ZZhejiang Cancer Hospital·Phase 1/2·NCT06572319·35 enrolled

Bile Duct Adenocarcinoma1 trial

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06383533·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Disitamab Vedotin Plus Cadonilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Disitamab Vedotin Plus Cadonilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Disitamab Vedotin Plus Cadonilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang Cancer Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: ZZhejiang Cancer Hospital

Disitamab Vedotin Plus Cadonilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Disitamab Vedotin1 trial

Bile Duct Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News